Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 16/20 | 0.38 |
| ▸ | JAK1 | P23458 | 16/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17872111 | 0.88 | KMT2A (0.40) | C5AR1MKNK1 | |
| SCHEMBL23260770 | 0.88 | C5AR1 (0.36) | C5AR1JAK2JAK1MKNK1 | |
| SCHEMBL17872084 | 0.86 | KIF11 (0.37) | C5AR1JAK2JAK1MKNK1 | |
| SCHEMBL17872086 | 0.83 | MAPT (0.40) | — | |
| SCHEMBL3468583 | 0.81 | CCNA2 (0.45) | C5AR1MKNK1 | |
| SCHEMBL19312086 | 0.81 | C5AR1 (0.35) | C5AR1JAK2JAK1 | |
| SCHEMBL3331339 | 0.79 | C5AR1 (0.34) | C5AR1 | |
| SCHEMBL596325 | 0.79 | ADORA1 (0.38) | C5AR1 | |
| SCHEMBL16622327 | 0.79 | C5AR1 (0.37) | C5AR1 | |
| SCHEMBL17872128 | 0.78 | KDM4E (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3236959-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| EP-3236959-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Dana Farber Cancer Institute, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | C5AR1 2348/4885JAK2 698/4885JAK1 338/4885 |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | C5AR1 2348/4885JAK2 698/4885JAK1 338/4885 |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | C5AR1 2468/4885JAK2 681/4885JAK1 393/4885 |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | C5AR1 2348/4885JAK2 698/4885JAK1 338/4885 |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | C5AR1 2348/4885JAK2 698/4885JAK1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.